原发中枢神经系统淋巴瘤治疗进展  

Treatment Advances of Primary Central Nervous System Lymphoma

作　　者：周倩倩[1] 易嘉宁[1] 易平勇[1] 

机构地区：[1]中南大学湘雅医学院附属肿瘤医院淋巴瘤血液内科,湖南长沙410013

出　　处：《肿瘤药学》2015年第3期161-167,共7页Anti-Tumor Pharmacy

摘　　要：原发中枢神经系统淋巴瘤目前尚无最佳治疗方案,以高剂量甲氨蝶呤(HD-MTX)为基础的化疗是目前推荐的一线治疗方案。利妥昔单抗治疗原发中枢神经系统淋巴瘤已初见疗效,但尚需临床试验确定。HD-MTX加巩固放疗能提高缓解率,但是由于其延迟神经毒性,并不能延长总生存期,是否需要巩固放疗仍存在争议。大剂量化疗+自体干细胞移植(HDC+ASCT)是原发中枢神经系统淋巴瘤有效的巩固及挽救治疗方法,其最佳治疗方案仍需进一步探索。Currently, since there is no optimal standard treatment regimen for primary central nervous system lymphoma （PCNSL）, the high-dose methotrexate （HD-MTX） based chemotherapy is the recommended first-line therapy. Rituximab in PCNSL treatment has shown signs of efficacy but still requires adequate clinical randomized trials to prove. HD-MTX plus consolidation radiotherapy can improve the response rate, but the treatment regimen can not prolong overall survival due to delayed neurotoxicity, so it is controversial yet to adopt consolidate radiotherapy. High-dose chemotherapy with autologous stem cell transplantation （HDC ＋ ASCT） is the effective consolidation and salvage therapy for PCNSL, but its optimal regi- men needs further exploration.

关 键 词：中枢神经系统淋巴瘤 化疗 放疗 造血干细胞移植 

分 类 号：R733.4[医药卫生—肿瘤]